The results of a retrospective study comparing the efficacy of ICIs in patients with uncommon versus common EGFR mutations in advanced NSCLC suggested that uncommon EGFR mutations (G719X, n = 9) were associated with a higher median PFS and ORR than common mutations (mPFS: 2.5 months vs. 1.82 months; ORR: 25% vs. 10.94%), although median OS did not significantly differ between the groups [61]. Here, EGFR is linked to non-small cell lung carcinoma.